Go online to PeerView.com/ZBX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Treatment advances in metastatic melanoma have been characterized by the use of immunotherapy, including PD-1 and CTLA-4 checkpoint inhibitors, as well as targeted agents in BRAF-mutated disease—and collectively these modalities represent the driving forces leading to improved clinical outcomes across disease settings. How will new evidence change this current paradigm? In this MasterClass & Case Forum video activity, based on a live event at the 2022 ASCO Annual Meeting, an expert panel explores the latest practice-changing clinical evidence for managing BRAF-mutated melanoma, while providing case-based practical guidance on modern treatment decisions with immunotherapy and targeted agents. Learn how these experts are using novel immune-based options in this setting to improve outcomes for their patients with BRAF-mutated disease. Upon completion of this activity, participants should be better able to: Cite current evidence on the efficacy of modern sequential approaches to using immunotherapy and targeted regimens in the setting of BRAF-mutated, metastatic melanoma; Utilize optimized strategies with immunotherapy components for the initial and sequential management of patients with BRAF-mutated, metastatic melanoma; and Develop team-based, collaborative strategies for managing toxicity associated with the sequential use of immunotherapy and targeted agents in patients with metastatic melanoma.